Join us in-person for the 2025 DTRF "Together We Will" Weekend in Chicago from Sept. 12-13! - Register Today

The Desmoid Tumor Research Foundation

July 2017

Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors

Author Information

Moding EJ(1), Million L(1), Avedian R(2), Ghanouni P(3), Kunder C(4), Ganjoo KN(5)

(1)Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.(2)Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, USA.(3)Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.(4)Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.(5)Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.

Publication

Sarcoma

Summary

To achieve more rapid symptomatic relief and tumor regression for unresectable desmoid tumors causing significant morbidity such as brachial plexus impingement with loss of extremity function, we have selectively utilized a combination of imatinib and radiation therapy. Here, we retrospectively review four patients treated with concurrent imatinib and radiation therapy. The treatment was typically tolerated with minimal toxicity though one patient developed avascular necrosis of the irradiated humeral head possibly related to the combined treatment. All the patients treated have had a partial response or stable disease on imaging. Improvement of symptoms was observed in all the treated patients with a median time to relief of 2.5 months after starting radiation therapy. Concurrent radiation and imatinib may represent a viable treatment option for unresectable and symptomatic desmoid tumors where rapid relief is needed to prevent permanent loss of function.

View Abstract